Previous studies have revealed that treatment responses to several IL-17 inhibitors (such as secukinumab and brodalumab) could be affected by the body mass index (BMI) of patients with psoriasis (Huang et al., 2020; Rompoti et al., 2023). Here, IL17A is linked to psoriasis.